Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by ANALIAS00on Apr 15, 2022 3:49pm
135 Views
Post# 34606807

RE:RE:RE:RE:RE:RE:RE:Shareholders Right Agreement just filed

RE:RE:RE:RE:RE:RE:RE:Shareholders Right Agreement just filedTjey cant attract good analyst, they can manage to make.good finamce deal, they cant find partners, no one want to buy their shares so I cant be worry about a takeover.
Wino115 wrote: I wouldn't worry too much.  It's fairly rare for hostiles in biotech because you'd need to understand the science in depth prior to doing anything. In some ways it helps us since it creates a buffer time period where other players can come in in look --provided there's a reason to look first!!  We need to get there before even bothering to worry about this.  But it's not necessarily bad and a rare feat in biotech anyway.

ANALIAS00 wrote: Zut. De zut !

Damn !

:o)

palinc2000 wrote: Hostile take over






<< Previous
Bullboard Posts
Next >>